31 days
Time to First Decision

Most Cited

Article

526 Views

17 Pages

A Mechanistic Dynamic Surrogate Framework for Personalized Radioactive Iodine Therapy in Metastatic Thyroid Cancer

Marie Fusella Giuntini,
Cyril Voyant,
David Taieb and
Dominique Barbolosi

Precis. Oncol.2026, 1(1), 2;https://doi.org/10.3390/precisoncol1010002

10 December 2025

Background/Objectives: Radioactive iodine (RAI) therapy is widely used to treat metastatic differentiated thyroid cancer. To investigate physiological determinants of treatment response, a mechanistic model was developed, formulated as a system of co...

Full Article

Editorial

136 Views

2 Pages

Establishing a Prestigious Platform for Discovery, Innovation, and Excellence in Precision Oncology

Raul A. Urrutia

Precis. Oncol.2026, 1(1), 3;https://doi.org/10.3390/precisoncol1010003

20 January 2026

It is with great honor and satisfaction that I write this introductory Editorial for the launch of Precision Oncology, focused on a transformational discipline in the field of precision medicine for cancer [...]

Full Article

Case Report

1,666 Views

7 Pages

Treatment of Resistant TPM3::ALK + Fusion Protein Metastatic Inflammatory Myofibroblastic Tumor with ALK Targeting and Immune Checkpoint Inhibitor Combined Therapy

Leonardo Simonelli,
Sebastian James Khairkhahan,
Francesco Alessandrino,
Elizabeth Anne Montgomery and
Gina D’Amato

Precis. Oncol.2026, 1(1), 1;https://doi.org/10.3390/precisoncol1010001

20 August 2025

Background and Clinical Significance: Inflammatory myofibroblastic tumors (IMTs) are rare neoplasms with low metastatic potential but a high recurrence rate. Approximately 60–80% of IMTs harbor anaplastic lymphoma kinase (ALK) gene rearrangemen...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Precis. Oncol. - ISSN 3042-7614

Imprint